ABC 294640

Drug Profile

ABC 294640

Alternative Names: ABC294640; YELIVA

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apogee Biotechnology Corporation
  • Developer Apogee Biotechnology Corporation; Louisiana State University Health Sciences Center; Medical University of South Carolina; RedHill Biopharma
  • Class Adamantanes; Anti-inflammatories; Antineoplastics; Antirheumatics; Pyridines; Small molecules
  • Mechanism of Action Sphingosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Phase I/II Diffuse large B cell lymphoma; Kaposi's sarcoma; Multiple myeloma
  • Phase I Solid tumours
  • Clinical Phase Unknown Cancer
  • Preclinical Cholangiocarcinoma; Inflammatory bowel diseases; Osteoarthritis; Prostate cancer; Radiation injuries; Rheumatoid arthritis

Most Recent Events

  • 18 Sep 2017 RedHill Biopharma receives patent allowance for Yeliva® and Mesupron in USA
  • 18 Sep 2017 Clinical trials in Cancer (Combination therapy) in USA (PO)
  • 10 Aug 2017 RedHill Biopharma plans a phase IIa trial for Cholangicarcinoman fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top